Real-time Estimate
Cboe BZX
02:55:23 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
4.365
USD
|
+5.43%
|
|
-60.72%
|
-70.38%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
216.4
|
247.8
|
518.4
|
148.8
|
-
|
-
|
Enterprise Value (EV)
1 |
216.4
|
247.8
|
518.4
|
148.8
|
148.8
|
148.8
|
P/E ratio
|
-4.28
x
|
-3.01
x
|
-4.22
x
|
-1.01
x
|
-1.14
x
|
-1.05
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
69.4
x
|
47.3
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
69.4
x
|
47.3
x
|
EV / EBITDA
|
-
|
-2.99
x
|
-4.16
x
|
-0.93
x
|
-0.83
x
|
-0.69
x
|
EV / FCF
|
-5.6
x
|
-3.91
x
|
-
|
-1.11
x
|
-1.01
x
|
-0.81
x
|
FCF Yield
|
-17.8%
|
-25.6%
|
-
|
-90%
|
-99.2%
|
-123%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
29,045
|
29,396
|
35,706
|
35,945
|
-
|
-
|
Reference price
2 |
7.450
|
8.430
|
14.52
|
4.140
|
4.140
|
4.140
|
Announcement Date
|
2/28/22
|
3/28/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
2.143
|
3.143
|
EBITDA
1 |
-
|
-
|
-82.94
|
-124.6
|
-160.4
|
-179.1
|
-216.6
|
EBIT
1 |
-
|
-41.67
|
-83.63
|
-126.1
|
-159.3
|
-176
|
-209.9
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-8,215.17%
|
-6,677.43%
|
Earnings before Tax (EBT)
1 |
-
|
-41.57
|
-81.83
|
-117.3
|
-155.4
|
-175
|
-212.3
|
Net income
1 |
-5.324
|
-41.57
|
-81.83
|
-117.3
|
-155.1
|
-173.9
|
-208.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-8,113.84%
|
-6,630.61%
|
EPS
2 |
-0.5000
|
-1.740
|
-2.800
|
-3.440
|
-4.109
|
-3.629
|
-3.947
|
Free Cash Flow
1 |
-
|
-38.61
|
-63.45
|
-
|
-134
|
-147.7
|
-183.3
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-6,891.1%
|
-5,833.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/12/21
|
2/28/22
|
3/28/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-17.3
|
-23.31
|
-26.1
|
-29.74
|
-27.27
|
-30.7
|
-36.91
|
-
|
-40.05
|
-40.1
|
-39.93
|
-
|
-
|
EBIT
1 |
-14.74
|
-16.4
|
-17.47
|
-23.48
|
-26.28
|
-30.03
|
-27.66
|
-31.12
|
-37.33
|
-37.33
|
-40.92
|
-39.34
|
-37.97
|
-40
|
-41.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.71
|
-16.37
|
-17.26
|
-22.89
|
-25.31
|
-29.05
|
-24.89
|
-28.43
|
-34.88
|
-34.88
|
-38.8
|
-38.14
|
-37.4
|
-40
|
-41.5
|
Net income
1 |
-14.71
|
-16.37
|
-17.26
|
-22.89
|
-25.31
|
-29.05
|
-24.89
|
-28.43
|
-34.88
|
-34.88
|
-38.61
|
-37.98
|
-37.57
|
-40
|
-41.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5100
|
-0.5600
|
-0.5900
|
-0.7800
|
-0.8600
|
-0.9800
|
-0.7000
|
-0.8000
|
-0.9800
|
-0.9800
|
-1.072
|
-1.020
|
-0.9571
|
-1.090
|
-1.130
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/16/22
|
8/1/22
|
11/7/22
|
3/28/23
|
5/2/23
|
7/31/23
|
10/30/23
|
3/28/24
|
4/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-38.6
|
-63.4
|
-
|
-134
|
-148
|
-183
|
ROE (net income / shareholders' equity)
|
-
|
-45.2%
|
-57%
|
-
|
-85.6%
|
-79%
|
-91.3%
|
ROA (Net income/ Total Assets)
|
-
|
-33.5%
|
-52%
|
-
|
-74.1%
|
-76%
|
-73.6%
|
Assets
1 |
-
|
124.1
|
157.5
|
-
|
209.2
|
228.8
|
283.1
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
3.17
|
1.03
|
-
|
2.76
|
3.3
|
3.35
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
154%
|
106.59%
|
Announcement Date
|
4/12/21
|
2/28/22
|
3/28/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
4.14
USD Average target price
35.17
USD Spread / Average Target +749.44% Consensus |
1st Jan change
|
Capi.
|
---|
| -70.38% | 149M | | +48.38% | 57.87B | | +41.65% | 40.25B | | -6.63% | 39.94B | | -5.96% | 28.54B | | +13.12% | 26.4B | | -20.20% | 19.33B | | +31.47% | 12.4B | | +0.49% | 12.23B | | +24.86% | 12.2B |
Other Biotechnology & Medical Research
|